- Home
- OPTT vs BCAB Comparison
OPTT vs BCAB Comparison
Compare OPTT & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPTT | BCAB |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 71.6M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPTT | BCAB |
|---|---|---|
| Price | $0.30 | $0.78 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $1.50 | $1.00 |
| AVG Volume (30 Days) | ★ 2.5M | 2.1M |
| Earning Date | 12-15-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000.00 | N/A |
| Revenue This Year | $94.90 | N/A |
| Revenue Next Year | $74.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.38 | N/A |
| 52 Week Low | $0.27 | $0.24 |
| 52 Week High | $1.75 | $1.53 |
Technical Indicators
Market Signals| Indicator | OPTT | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 47.86 |
| Support Level | $0.41 | $0.79 |
| Resistance Level | $0.46 | $0.90 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 0.19 | 23.68 |
Price Performance
Historical ComparisonAbout OPTT Ocean Power Technologies Inc.
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.